TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9543117
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (714 mg Ca/day)
Study: 17615800
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin (5000 IU) once daily
Study: 15543329
Drug: Vitamin K(1)-containing
Normalized name: vitamin K 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K(1)-containing multivitamin (25 mcg daily for 4 weeks)
Study: 11994558
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination drug therapy with glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytics
Study: 9685777
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics during intracranial pressure monitoring
Study: 7863722
Drug: Chewable pyrantel
Normalized name: pyrantel Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable pyrantel pamoate tablets (swallow whole)
Study: 24129363
Drug: 100 g-organic naked
Normalized name: castor oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g-organic naked oat with whole germ group (ONOG)
Study: 24129363
Drug: 50 g-organic naked
Normalized name: castor oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g-organic naked oat with whole germ group (ONOG)
Study: 20147968
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of fermented milk (FM)
Study: 20147968
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml of fermented milk (FM)
Study: 31362034
Drug: Bi-anodal tDCS
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-anodal tDCS (2 mA, twice-daily sessions for five consecutive days)
Study: 28913630
Drug: Oral Appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Appliance Therapy (OAT)
Study: 17584705
Drug: Nitroglycerine sublingual
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine sublingual application
Study: 31203197
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa eradication therapy
Study: 31162787
Drug: Tapentadol sustained-release
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol sustained-release
Study: 17163096
Drug: Adjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapies including anthracycline- and taxane-based polychemotherapeutics, trastuzumab, with or without endocrine manipulation and with or without PMRT
Study: 1875221
Drug: NABM infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NABM infusion after CVP
Study: 25557395
Drug: Ongoing outpatient
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing outpatient therapy
Study: 11894705
Drug: Intensive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive physical therapy (3.6 hours/week)
Study: 314777
Drug: High-dosage ampicillin
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage ampicillin (400 mg/kg per day)
Study: 31888701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of male-focused mobilization, community-based mobile HIV testing services, and a small incentive.
Study: 7489472
Drug: Morphine 50
Normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 50 or 100 micrograms.kg‐1
Study: 12365881
Drug: Compensated Work
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compensated Work Therapy (CWT)
Study: 7752752
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g
Study: 12010356
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 100-400 mg
Study: 10543411
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg glimepiride
Study: 17062365
Drug: FGF 2
Normalized name: FGF 2
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 2 L/min with 2% isoflurane
Study: 1390326
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg once a day
Study: 23106926
Drug: Days of
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days of maternal study medication received
Study: 31140940
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of orally administered alpha lipoic acid (ALA) once a day during the 12‐week period
Study: 28575536
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment
Study: 12432337
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg p.o. 12 days/month
Study: 12432337
Drug: Transdermic nor-ethisterone
Normalized name: ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermic nor-ethisterone acetate (NETA) 0.25 mg integrated in the ethinil-estradiol patches for the last two weeks of each cycle
Study: 10628599
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (peak inflation pressure ≤50 cm H2O, tidal volume 10-15 mL/kg)
Study: 16305563
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 80 mg/1.5 mL gel solution
Study: 19114685
Drug: Panitumumab added
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab added to bevacizumab and chemotherapy (oxaliplatin-based)
Study: 3291523
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection therapy
Study: 12458394
Drug: Insulin-stimulated myocardial
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-stimulated myocardial glucose uptake measured during hyperinsulinaemic euglycaemic glucose clamp with fluorine‐18 fluorodeoxyglucose.
Study: 8427429
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nalmefene IV
Study: 29172732
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Irbesartan + Trichlormethiazide/Amlodipine/Efonidipine)
Study: 22954563
Drug: High-concentration sodium
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration sodium bicarbonate (833 mEq/L, n = 87)
Study: 22954563
Drug: Low-concentration sodium
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration sodium bicarbonate (160 mEq/L, n = 36)
Study: 8889259
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (dry powder 20 mg per inhalation and aqueous nasal spray 5.2 mg per dose)
Study: 27042750
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH) treatment with 25(OH)D above the 50th percentile
Study: 22454414
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² IV over 1 hour for 21 days plus prednisone 5 mg orally twice per day plus bevacizumab 15 mg/kg IV every 3 weeks (DP + B)
Study: 16913498
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine
Study: 25336114
Drug: Infliximab concentrations
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab concentrations > 2.79 μg/mL
Study: 9545673
Drug: Cefopzopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefopzopran (CZOP) 20.0 mg/kg
Study: 9545673
Drug: Cefopzopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefopzopran (CZOP) 25.0 mg/kg
Study: 22851554
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m² on day 1 of course one of therapy
Study: 12624625
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (2‐8 micro g/min)
Study: 3581030
Drug: CHOP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP with intermediate dose methotrexate
Study: 16287344
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g dextrose as placebo (PL)
Study: 11951158
Drug: High-intensity training
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity training program on cycle ergometers (5 training units weekly at 40 minutes each for a minimum of 22 training units during 4 weeks)
Study: 24912456
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) for BD
Study: 12776949
Drug: Low-dosage Group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage Group (1.5 mg/kg of heparin)
Study: 30175648
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 8 weekly sessions of 45-60 minutes each.
Study: 16505497
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg
Study: 9824184
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (initial 6 g intravenous bolus followed by continuous infusion therapy 2 to 6 g/hr)
Study: 15820077
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (VC) - intravenously injected with an equal dose of aqueous carboplatin.
Study: 10689885
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium volume of 2.0 <, < or = 2.5 ml/kg
Study: 19294387
Drug: CI-1033 450
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-1033 450 mg/day x 14 days every 21 days (arm C)
Study: 11502525
Drug: Clinafloxacin (CI‐960)
Normalized name: Finafloxacin
DrugBank: Clinafloxacin (DB14025)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinafloxacin (CI‐960) administered intravenously and orally, dosage not specified, single and twice-daily doses.
Study: 8896541
Drug: High-titer vaccine
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer vaccine
Study: 8896541
Drug: Low-titer vaccine
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-titer vaccine
Study: 21108824
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitors
Study: 22950716
Drug: Intensified physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified physical activity counseling (5 sessions integrated into routine maternity visits, monthly group meetings)
Study: 28803087
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT)
Study: 25677254
Drug: Combination (Comb)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (Comb)
Study: 29915988
Drug: Preoperative carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrate beverage (400 mL evening before and 400 mL morning before surgery)
Study: 24335445
Drug: AZD9773 low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZD9773 low dose
Study: 24335445
Drug: AZD9773 high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9773 high dose
Study: 15772571
Drug: EPT every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPT every other day (0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Study: 23599045
Drug: GLP-1 (7-36
Normalized name: GLP-1 (7-36) amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (7-36 amide) infusion
Study: 9645593
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP), 400 microg twice a day
Study: 28958502
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg/day
Study: 25846055
Drug: Delayed-release 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed-release 6-mercaptopurine (DR-6MP)
Study: 31172717
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone
Study: 476709
Drug: Previous chemotherapy
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous chemotherapy with nitrosourea
Study: 29903026
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional medication)
Study: 7021070
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g enteric-coated aspirin daily
Study: 30855743
Drug: methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methyl aminolevulinate photodynamic therapy (MAL‐PDT)
Study: 2060150
Drug: Pyridostigmine 60
Normalized name: pyRIDostigmine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 60 mg
Study: 9825502
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to bacterial antigens (Reglicolipid, Streptococcus agalactiae polysaccharide, Staphylococcus aureus teichoic acid)
Study: 23765409
Drug: Having negative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Having negative views on generic medicines
Study: 6139671
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (100 mg three times a day)
Study: 23538523
Drug: MMR+V coadministered
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMR+V coadministered with DTaP‐IPV‐Hep B‐PRP‐T vaccine
Study: 6307964
Drug: IV dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of 441 mg ampicillin and 294 mg sulbactam
Study: 9045106
Drug: Inactivated Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Lactobacillus acidophilus LB with rehydratant treatment for acute enteritis
Study: 2222986
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of baclofen
Study: 31190490
Drug: Venlafaxine hydrochloride
Normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine hydrochloride (75 mg/day in 1st week, 150 mg/day in 2nd week, 225 mg/day from 3rd to 6th week)
Study: 22176998
Drug: Optimization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of medical treatment with β-blockers and angiotensin-converting enzyme inhibitors
Study: 18318568
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg administered as a 15-minute infusion every 3-4 weeks
Study: 10668449
Drug: NPS 1506
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPS 1506 (doses ranging from 5-100 mg i.v.)
Study: 11422263
Drug: Diazolidinyl urea
Normalized name: Diazolidinyl urea
DrugBank: Diazolidinylurea (DB14173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazolidinyl urea (DU) patch test at concentrations from 0 to 600 microg/cm(2)
Study: 31574170
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L polyethylene glycol plus ascorbic acid with bisacodyl suppository
Study: 23359968
Drug: UDCA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA and Fuzheng Huayu Capsule (FHC)
Study: 21443536
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg
Study: 19733712
Drug: Full drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full drug-eluting stenting (full DES)
Study: 11502527
Drug: Clinafloxacin 400
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinafloxacin 400 mg
Study: 7961554
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (initial 6-week trial)
Study: 16604429
Drug: 30-session drug
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-session drug prevention program in 7th through 9th grades
Study: 2876744
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g sulphasalazine daily for six months
Study: 1397669
Drug: Typhoid Vi
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi CPS vaccine
Study: 1530028
Drug: Exogenous human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +4 (group IV)
Study: 23059918
Drug: Dexamethasone ointment
Normalized name: DEXAMETHASONE 0.075 g in 100 g TOPICAL OINTMENT [Seacall Dexamethasone Ointment.]
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone ointment (5 g tube containing 5 mg dexamethasone)
Study: 7642415
Drug: Alternating chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemo-radiotherapy (Cisplatin 20 mg/mq and 5-Fluorouracil 200 mg/mq daily for 5 days) with two cycles of 20 Gy/10 fractions/12 days each.
Study: 11975819
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral sumatriptan
Study: 4005103
Drug: Desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine hydrochloride (50 mg twice daily)
Study: 8953680
Drug: ornidazole 40
Normalized name: ornidazol
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ornidazole 40 mg/kg as a single dose
Study: 24819761
Drug: Oral bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bovine LF 100 mg
Study: 16123958
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus with mycophenolate mofetil
Study: 12500511
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine 1.5 mg/kg
Study: 10402336
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine 2 mg/kg
Study: 29889698
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone (1 mg) with 15 mL bupivacaine 0.5%
Study: 11851956
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) of diethylcarbamazine (DEC) plus ivermectin (IVR)
Study: 30705241
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (usual speech therapy from local therapist for 6 weeks)
Study: 19847319
Drug: Glucosamine and
Normalized name: Glucosamine and Chondroitin Complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine and chondroitin (G+C)